
    
      This local, non-interventional, multicenter, single-cohort study using primary data includes
      patients treated with Mirena for Heavy menstrual bleeding(HMB) and/or dysmenorrhea
      (contraception is not included).

      A total of 600 patients (valid for safety analysis) is planned to be enrolled in two years.
      No formal sample size estimation was conducted, it was determined based on feasibility.

      Target population is patients with HMB and/or dysmenorrhea diagnosis. The treatment should be
      performed based on the product label in Japan. The standard observation period will last for
      12 months from starting Mirena treatment.
    
  